Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
ACS Chem Neurosci. 2022 Mar 2;13(5):540-551. doi: 10.1021/acschemneuro.1c00810. Epub 2022 Feb 8.
Alzheimer's disease (AD) is a high mortality and high disability rates neurodegenerative disease characterized by irreversible progression and poses a significant social and economic burden throughout the world. However, currently approved AD therapeutic agents only alleviate symptoms and there is still a lack of practical therapeutic regimens to stop or slow the progression of this disease. Thus, there is urgently needed novel diagnosis tools and drugs for early diagnosis and treatment of AD. Among several AD pathological hallmarks, amyloid-β (Aβ) peptide deposition is considered a critical initiating factor in AD. In recent years, with the advantages of excellent sensitivity and high resolution, near-infrared fluorescence (NIRF) imaging has attracted the attention of many researchers to develop Aβ plaque probes. This review mainly focused on different NIRF probe design strategies for imaging Aβ species to pave the way for the future design of novel NIRF probes for early diagnosis AD.
阿尔茨海默病（AD）是一种高死亡率和高致残率的神经退行性疾病，其特征为不可逆转的进展，在全球范围内造成了重大的社会和经济负担。然而，目前批准的 AD 治疗药物仅能缓解症状，仍然缺乏实用的治疗方案来阻止或减缓这种疾病的进展。因此，迫切需要新的诊断工具和药物来早期诊断和治疗 AD。在 AD 的几种病理特征中，淀粉样β（Aβ）肽沉积被认为是 AD 的关键起始因素。近年来，近红外荧光（NIRF）成像以其出色的灵敏度和高分辨率的优势，引起了许多研究人员的关注，用于开发 Aβ斑块探针。本综述主要集中于不同的 NIRF 探针设计策略，用于成像 Aβ 物种，为未来设计用于早期诊断 AD 的新型 NIRF 探针铺平道路。
